
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. demonstrated robust financial performance, with Cell Processing revenue reaching $23 million, reflecting a 28% year-over-year increase and a 6% quarter-over-quarter growth. Additionally, the company raised its 2025 revenue guidance to $100-103 million, indicating anticipated overall growth of 22-25% year-over-year, driven largely by the strong performance in Cell Processing. Furthermore, management has indicated a projected reduction in net loss and an expansion of adjusted EBITDA margin, underscoring the potential for continued growth and improved profitability.
Bears say
BioLife Solutions Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from lower than projected growth in its product and service offerings. The company's recent financial performance indicated a net loss of $15.8 million, or ($0.33) per share, which was substantially higher than anticipated due to considerable expenses linked to ongoing research and development, particularly related to the PanTHERA transaction. Additionally, risks surrounding customer acquisition, fluctuating sales in emerging markets, foreign exchange volatility, and potential dilution further exacerbate the uncertainties affecting the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares